Hints and tips:
Showing results for Shelle et al v. Eli Lilly And Company, Inc.
...Many French cinema owners, who are putting pressure on Cannes to resist Netflix et al, see the streamers’ disruptive attitude as an incursion into their territory....
...Rival Eli Lilly announced job cuts and a focus on new medicines while AstraZeneca was boosted by good news on its cancer pipeline....
...) Eli Lilly mulls spin-off or sale of animal health business (FastFT) Cargill ramps up animal nutrition business with Diamond V deal (FastFT) Asian buyers tap into ‘pampered pooch’ market (FT) ICE to...
...Eli Lilly, the US drugmaker, is due to publish data later this year from a large study of its drug, Solanezumab, which is also designed to slow down Alzheimer’s by clearing the brain of amyloid plaques....
...(FT) High stakes In a few weeks, the world will know whether Sola — a drug that pharma group Eli Lilly has spent many years developing — really does slow Alzheimer’s disease....
...Eli Lilly, up 2.4 per cent, and Sanofi, which added 1.6 per cent....
...The latest case, Google v Joffe et al, involves a class action suit stemming from the company’s illicit collection of snippets of information from WiFi networks in homes that its StreetView cars were passing...
...Lilly and current chairman of PhRMA, the trade body....
...While the black taffeta evening gowns and sturdy looking peacoats on Karlie Kloss et al shouted winter, the models’ peachy complexions were all spring – try Bobbi Brown’s Sheer Color Cheek Tint in Sheer...
...United States v Apple, Inc et al is more than a US Justice department antitrust action against publishers allegedly colluding on ebook prices....
...The case (now called FCC v. Fox Television Stations et al) was appealed to the US Supreme Court, where it was debated on Tuesday....
...But companies can also sell 8m pills, worth SR72m a year, of erectile dysfunction drugs such as Eli Lilly’s Cialis and Snafi, which are not subsidised....
...The chief executive of Eli Lilly has criticised the current round of “mega-mergers” in the pharmaceuticals industry and ruled out his own company’s participation, in spite of pressure for further consolidation...
...The Company intends to ask the Court to dismiss this matter on various grounds. Freddie Mac and Fannie Mae (on behalf of) suing in NYC and DC: Bassman v. Syron, et. al (FRE) Agnes v....
...There can be little doubt that Eden et al will achieve or better the top-of-the-band pricing of $18.50-a-share....
International Edition